As a JAK1 selective inhibitor, itacitinib is also under active investigation for prophylaxis of GVHD and may be effective at preventing both GVHD and CRS without increasing incidence of engraftment failure compared to other less selective JAK inhibitors. Here, JAK1 is linked to congenital rubella syndrome.